John Richart, MD
Hematology & Oncology · St Louis, MONPI 1659480242
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.5% of the total across 10 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Merck at 31.2% of the total. Reporting peaked in 2022 at $99 and has fallen 62.7% since, to $37 in 2023. That places this record below the midpoint for hematology & oncology clinicians in MO, where the typical reported total is $1,571.
Across 10 payments — averaging $14.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$46
- Pharmacyclics LLC, An Abbvie Company$37
- Bristol Myers Squibb$20
- Johnson & Johnson$19
- Acrotech Biopharma Inc.$14
- Amgen$11
Across 101 payments — averaging $4820.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$367K
- EMD Serono, Inc.$96K
- Sobi, Inc$24K
What the payments were for
- Food & beverage$13390%
- Education$1410%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 4 | $46 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $37 |
| Bristol Myers Squibb | 1 | $20 |
| Johnson & Johnson | 1 | $19 |
| Acrotech Biopharma Inc. | 1 | $14 |
| Amgen | 1 | $11 |
How this compares
$147 in reported general payments places this provider in the 15th percentile of 211 hematology & oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| WeliregBelzutifan | 11 | $312,618 |
| RydaptMidostaurin | 12 | $261,592 |
| CabometyxCabozantinib S-Malate | 11 | $253,873 |
| CalquenceAcalabrutinib Maleate | 12 | $184,783 |
| VenclextaVenetoclax | 30 | $105,872 |
| XareltoRivaroxaban | 17 | $15,205 |
| Posaconazole | 18 | $13,125 |
| ValacyclovirValacyclovir Hcl | 44 | $1,652 |
| GengrafCyclosporine, Modified | 16 | $1,357 |
| Voriconazole | 11 | $1,356 |
| Fentanyl | 16 | $1,019 |
| Morphine Sulfate ErMorphine Sulfate | 35 | $970 |
| Oxycodone Hcl | 32 | $792 |
| Levothyroxine Sodium | 26 | $464 |
| Prochlorperazine Maleate | 18 | $318 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckWelireg | $46 | $312,61811 claims |
| Johnson & JohnsonXarelto | $19 | $15,20517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 211 hematology & oncology providers in Missouri.
Other hematology & oncology in St Louis
- David SchlossmanColumbia$1.2M
- Mark FeslerSaint Louis$870K
- Kelly PendergrassLees Summit$189K
- Jonathan MizrahiSaint Louis$188K
- Shahzad RazaKansas City$123K
- Stephanie GraffKansas City$105K
- Muhammad MirzaWashington$65K
- Yifan TuSt. Louis$64K
- Whitney HensingKansas City$62K
- Shadi HaddadinJefferson City$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.